1. Guidance for Industry. The Content and Format for Pediatric Use Supplements. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 1996.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071957.pdf
. Accessed 15 Feb 2017.
2. European Medicines Agency. The European paediatric initiative: History of the Paediatric Regulation (EMEA/17967/04 Rev 1). 2007.
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf
. Accessed 15 Feb 2017.
3. Folgori L, Bielicki J, Ruiz B, et al. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis. 2016;16(9):e178–89.
4. European Medicines Agency. Concept paper on an addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2) to address paediatric-specific clinical data requirements (EMA/CHMP/213862/2016). 2016.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/04/WC500205026.pdf
. Accessed 15 Feb 2017.
5. Clinical Trials Transformation Initiative. Improving pediatric trials in antibacterial drug development: no sick child left behind. Summary of the Meeting held April 5, 2016.
https://www.ctti-clinicaltrials.org/files/ctti-pedstrials-expertmeeting-summary.pdf
. Accessed 15 Feb 2017.